PTH-receptors regulate norepinephrine release in human heart and kidney

Regulatory Peptides

Volumn 171, Issue 1-3, 2011, Pages 35-42

  Potthoff, S A ^a   Janus, A ^a   Hoch, H ^a   Frahnert, M ^b   Tossios, P ^c   Reber, D ^d   Giessing, M ^a   Klein, H M ^a   Schwertfeger, E ^e   Quack, I ^a   Rump, L C ^a   Vonend, O ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d RUHR UNIVERSITY BOCHUM   (Germany)

^e Dialyse Freiburg and Breisach Freiburg   (Germany)

Author keywords

Chronic renal failure; Norepinephrine release; Parathyroid hormone; PTH receptor; Tuberoinfundibular peptide of 39 residues

Indexed keywords

8 BROMO CYCLIC AMP; MESSENGER RNA; NORADRENALIN; PARATHYROID HORMONE RECEPTOR; PARATHYROID HORMONE RECEPTOR 1; PARATHYROID HORMONE RECEPTOR 2; PARATHYROID HORMONE[1-34]; TRITIUM;

ADULT; AGED; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTROSTIMULATION; HEART ATRIUM MUSCLE; HORMONAL REGULATION; HUMAN; HUMAN TISSUE; KIDNEY CORTEX; KIDNEY PARENCHYMA; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; NORADRENALIN RELEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESIDUE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGED; AGED, 80 AND OVER; ANIMALS; CELLS, CULTURED; COCAINE; CORTICOSTERONE; HEART; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; MICE; MIDDLE AGED; NEUROPEPTIDES; NOREPINEPHRINE; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; RECEPTOR, PARATHYROID HORMONE, TYPE 1; RECEPTOR, PARATHYROID HORMONE, TYPE 2; SYNAPTIC TRANSMISSION;

HELIOTHIS ZEA VIRUS 1;

EID: 80051808901     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2011.06.002     Document Type: Article

References (32)

1. Ligtenberg G., Blankestijn P.J., Oey P.L., Klein I.H., Dijkhorst-Oei L.T., Boomsma F., et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999, 340:1321-1328.
2. Rump L.C., Amann K., Orth S., Ritz E. Sympathetic overactivity in renal disease: a window to understand progression and cardiovascular complications of uraemia?. Nephrol Dial Transplant 2000, 15:1735-1738.
3. Zoccali C., Mallamaci F., Parlongo S., Cutrupi S., Benedetto F.A., Tripepi G., et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002, 105:1354-1359.
4. Ganesh S.K., Stack A.G., Levin N.W., Hulbert-Shearon T., Port F.K. Association of elevated serum PO(4), Ca×PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001, 12:2131-2138.
5. Rostand S.G., Drueke T.B. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 1999, 56:383-392.
6. Cohn J.N., Levine T.B., Olivari M.T., Garberg V., Lura D., Francis G.S., et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984, 311:819-823.
7. Francis G.S., Goldsmith S.R., Levine T.B., Olivari M.T., Cohn J.N. The neurohumoral axis in congestive heart failure. Ann Intern Med 1984, 101:370-377.
8. Hagstrom E., Ingelsson E., Sundstrom J., Hellman P., Larsson T.E., Berglund L., et al. Plasma parathyroid hormone and risk of congestive heart failure in the community. Eur J Heart Fail 2010.
9. Stegbauer J., Vonend O., Habbel S., Quack I., Sellin L., Gross V., et al. Angiotensin II modulates renal sympathetic neurotransmission through nitric oxide in AT2 receptor knockout mice. J Hypertens 2005, 23:1691-1698.
10. Stegbauer J., Vonend O., Oberhauser V., Sellin L., Rump L.C. Angiotensin II receptor modulation of renal vascular resistance and neurotransmission in young and adult spontaneously hypertensive rats. Kidney Blood Press Res 2005, 28:20-26.
11. Stegbauer J., Kuczka Y., Vonend O., Quack I., Sellin L., Patzak A., et al. Endothelial nitric oxide synthase is predominantly involved in angiotensin II modulation of renal vascular resistance and norepinephrine release. Am J Physiol Regul Integr Comp Physiol 2008, 294:R421-R428.
12. Bohmann C., Rump L.C., Schaible U., von Kugelgen I. Alpha-adrenoceptor modulation of norepinephrine and ATP release in isolated kidneys of spontaneously hypertensive rats. Hypertension 1995, 25:1224-1231.
13. Costa M., Majewski H. Facilitation of noradrenaline release from sympathetic nerves through activation of ACTH receptors, beta-adrenoceptors and angiotensin II receptors. Br J Pharmacol 1988, 95:993-1001.
14. Muayed M.E., Stegbauer J., Oberhauser V., Vonend O., Rump L.C. AT1 and AT2-receptor antagonists inhibit Ang II-mediated facilitation of noradrenaline release in human atria. J Cardiovasc Pharmacol 2004, 43:318-324.
15. Rump L.C., Schwertfeger E., Schaible U., Fraedrich G., Schollmeyer P. Beta 2-adrenergic receptor and angiotensin II receptor modulation of sympathetic neurotransmission in human atria. Circ Res 1994, 74:434-440.
16. Stegbauer J., Vonend O., Oberhauser V., Rump L.C. Effects of angiotensin-(1-7) and other bioactive components of the renin-angiotensin system on vascular resistance and noradrenaline release in rat kidney. J Hypertens 2003, 21:1391-1399.
17. Chorev M. Parathyroid hormone 1 receptor: insights into structure and function. Receptors Channels 2002, 8:219-242.
18. Turner P.R., Mefford S., Bambino T., Nissenson R.A. Transmembrane residues together with the amino terminus limit the response of the parathyroid hormone (PTH) 2 receptor to PTH-related peptide. J Biol Chem 1998, 273:3830-3837.
19. Usdin T.B., Bonner T.I., Hoare S.R. The parathyroid hormone 2 (PTH2) receptor. Receptors Channels 2002, 8:211-218.
20. Bisello A., Manen D., Pierroz D.D., Usdin T.B., Rizzoli R., Ferrari S.L. Agonist-specific regulation of parathyroid hormone (PTH) receptor type 2 activity: structural and functional analysis of PTH- and tuberoinfundibular peptide (TIP) 39-stimulated desensitization and internalization. Mol Endocrinol 2004, 18:1486-1498.
21. Ross G., Engel P., Abdallah Y., Kummer W., Schluter K.D. Tuberoinfundibular peptide of 39 residues: a new mediator of cardiac function via nitric oxide production in the rat heart. Endocrinology 2005, 146:2221-2228.
22. Eichinger A., Fiaschi-Taesch N., Massfelder T., Fritsch S., Barthelmebs M., Helwig J.J. Transcript expression of the tuberoinfundibular peptide (TIP)39/PTH2 receptor system and non-PTH1 receptor-mediated tonic effects of TIP39 and other PTH2 receptor ligands in renal vessels. Endocrinology 2002, 143:3036-3043.
23. Usdin T.B., Hoare S.R., Wang T., Mezey E., Kowalak J.A. TIP39: a new neuropeptide and PTH2-receptor agonist from hypothalamus. Nat Neurosci 1999, 2:941-943.
24. Bago A.G., Dimitrov E., Saunders R., Seress L., Palkovits M., Usdin T.B., et al. Parathyroid hormone 2 receptor and its endogenous ligand tuberoinfundibular peptide of 39 residues are concentrated in endocrine, viscerosensory and auditory brain regions in macaque and human. Neuroscience 2009, 162:128-147.
25. Rump L.C., Riess M., Schwertfeger E., Michel M.C., Bohmann C., Schollmeyer P. Prejunctional neuropeptide Y receptors in human kidney and atrium. J Cardiovasc Pharmacol 1997, 29:656-661.
26. Vonend O., Habbel S., Stegbauer J., Roth J., Hein L., Rump L.C. Alpha(2A)-adrenoceptors regulate sympathetic transmitter release in mice kidneys. Br J Pharmacol 2007, 150:121-127.
27. Block G.A., Port F.K. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000, 35:1226-1237.
28. Locatelli F., Cannata-Andia J.B., Drueke T.B., Horl W.H., Fouque D., Heimburger O., et al. Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant 2002, 17:723-731.
29. Augustyniak R.A., Tuncel M., Zhang W., Toto R.D., Victor R.G. Sympathetic overactivity as a cause of hypertension in chronic renal failure. J Hypertens 2002, 20:3-9.
30. Goold C.P., Usdin T.B., Hoare S.R. Regions in rat and human parathyroid hormone (PTH) 2 receptors controlling receptor interaction with PTH and with antagonist ligands. J Pharmacol Exp Ther 2001, 299:678-690.
31. Shimoyama M., Ogino K., Uchida K., Furuse Y., Kinugasa Y., Taniguchi S., et al. Fragment-specific actions of parathyroid hormone in isolated perfused rat hearts. Calcif Tissue Int 2001, 69:88-93.
32. Bergwitz C., Jusseaume S.A., Luck M.D., Juppner H., Gardella T.J. Residues in the membrane-spanning and extracellular loop regions of the parathyroid hormone (PTH)-2 receptor determine signaling selectivity for PTH and PTH-related peptide. J Biol Chem 1997, 272:28861-28868.